» Articles » PMID: 23847097

Emerging Role for the Voltage-dependent K+ Channel Kv1.5 in B-lymphocyte Physiology: Expression Associated with Human Lymphoma Malignancy

Abstract

Kv, which play a role in the immune system, are remodeled during carcinogenesis. Leukocytes present a limited Kv repertoire, with Kv1.3 and Kv1.5 as isoforms that are involved in neoplastic processes, such as proliferation and migration. In this study, we identified Kv1.5 in B-lymphocytes, characterized its role in proliferation and migration, and analyzed Kv1.3 and Kv1.5 expression in human non-Hodgkin lymphomas. DLBCL, F, MCL, ALCL, and T, along with control N specimens, were analyzed. Kv1.3 and Kv1.5 were found to be remodeled differentially; whereas Kv1.3 expression did not correlate with the state of dedifferentiation or the nature of lymphomatous cells, Kv1.5 abundance correlated inversely with clinical aggressiveness. Whereas indolent F expressed noticeable levels of Kv1.5, aggressive DLBCL showed low Kv1.5 levels. In addition, control LNs expressed heterogeneous high levels of Kv1.3, which could indicate some reactivity, whereas Kv1.5 abundance was low and quite homogeneous. Our data show that Kv1.5 is a determinant of human B cell proliferation and migration, thereby identifying this channel as a new target for immunomodulation. Our work also provides new insights into the use of Kv1.3 and Kv1.5 as potential targets during tumorigenesis.

Citing Articles

KCNAB2 overexpression inhibits human non-small-cell lung cancer cell growth in vitro and in vivo.

Cheng F, Tang Y, Cao Y, Peng S, Zhu X, Sun Y Cell Death Discov. 2023; 9(1):382.

PMID: 37852974 PMC: 10584983. DOI: 10.1038/s41420-023-01679-5.


Potassium Ion Channels in Malignant Central Nervous System Cancers.

Boyle Y, Johns T, Fletcher E Cancers (Basel). 2022; 14(19).

PMID: 36230692 PMC: 9563970. DOI: 10.3390/cancers14194767.


Potassium Channels as a Target for Cancer Therapy: Current Perspectives.

Zuniga L, Cayo A, Gonzalez W, Vilos C, Zuniga R Onco Targets Ther. 2022; 15:783-797.

PMID: 35899081 PMC: 9309325. DOI: 10.2147/OTT.S326614.


Peptide Inhibitors of Kv1.5: An Option for the Treatment of Atrial Fibrillation.

Borrego J, Feher A, Jost N, Panyi G, Varga Z, Papp F Pharmaceuticals (Basel). 2021; 14(12).

PMID: 34959701 PMC: 8704205. DOI: 10.3390/ph14121303.


Kv1.3 Controls Mitochondrial Dynamics during Cell Cycle Progression.

Capera J, Perez-Verdaguer M, Navarro-Perez M, Felipe A Cancers (Basel). 2021; 13(17).

PMID: 34503267 PMC: 8431373. DOI: 10.3390/cancers13174457.